I'm still not sure people get the full magnitude of CF33 (Vaxinia or Checkvacc) if successful, and yes, I say IF. Bantering numbers of $2 - 4 billion in a buyout is absurd. So let me put it another way: Let's say that it that it can do the same thing as Keytruda but has less toxicity and it becomes the 'go to' first line therapy. The patent is out to 2038 and let's say we get things all approved by 2024 (wishful thinking but just humour me). That leaves 14 years of protected first line global therapy. Keytruda sales are $21 US billion (and rising) annually. Over 14 years patent security, that's $294 US billion potential sales. Do you think that there's a BP out there that would consider this investment at $4 billion? Of course there is and that's why it would have to be double figures if the return is triple figures. It's a no brainer really. And that's only one of many in the IMU pipeline.
Not financial advice - just my opinion.
BD
IMU Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)